ALTURiX Acquires UK and Ireland Rights to Metolazone
Issued: London Tuesday 10th May 2022
Announced today, ALTURiX – a rapidly-growing British pharmaceutical company - has acquired the rights to metolazone for the United Kingdom and the Republic of Ireland following the finalisation of an agreement with SIT Laboratorio Farmaceutico.
Founded in 2020 following the acquisition of two family-owned pharmaceutical companies, ALTURiX has a portfolio of well-known medicines which are prescribed widely by the NHS. The mission set out by the ALTURiX founders is to reliably provide branded products at an appropriate price. ALTURiX was created and shaped to provide these high quality medicines to the NHS with streamlined efficiency.
The company portfolio includes three heritage, branded products acquired from Novartis - all proven and acknowledged to improve patients’ health. ALTURiX reliably supplies these products to the NHS and other international markets, using its manufacturing partner based in Switzerland. This is in keeping with the company’s commitment to reliably deliver high-quality products, at a sensible price.
In addition, for the last five years the company has been growing rapdily through a programme of new product acquisitions and market introductions.
Commenting on the agreement, Lak Sahota – Founder and Director at ALTURiX said,
“We are delighted to announce this important deal with SIT Laboratorio Farmaceutico. This is the latest example of our successful growth strategy, and further demonstrates the company’s commitment to reliably and affordably supply important products in markets where there are currently limited options available to patients and the NHS.”
Lamberto Pedrotti, CEO of SIT Laboratorio Farmaceutico further commented,
“SIT Laboratorio Farmaceutico is a family owned international pharmaceutical company with 90 years of experience and a recent history of global expansion. This agreement is an important opportunity to expand and diversify our business approach which is based on international acquisitions of mature branded medicines, and enter the UK market through a licencing partnership with ALTURiX to allow the medical community, and patients, to gain access to a high-therapeutic-value pharmaceutical product.”